How Many Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s Analysts Are Bullish?

October 13, 2018 - By Peter Erickson

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) LogoInvestors sentiment increased to 1.11 in 2018 Q2. Its up 0.05, from 1.06 in 2018Q1. It is positive, as 16 investors sold Ligand Pharmaceuticals Incorporated shares while 109 reduced holdings. 42 funds opened positions while 97 raised stakes. 22.99 million shares or 1.94% more from 22.56 million shares in 2018Q1 were reported.
First Republic Mgmt has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Wellington Management Llp has 4,244 shares. Massmutual Tru Fsb Adv owns 2,744 shares. Ashford Capital Mngmt has 85,577 shares for 2.34% of their portfolio. Dana Inv Advsr Inc invested in 13,206 shares. Morgan Stanley has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Glenmede Company Na holds 0.3% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 355,626 shares. Gsa Capital Partners Llp accumulated 7,462 shares. Gemmer Asset Mgmt Lc has 53 shares for 0% of their portfolio. First Advsrs Lp stated it has 22,760 shares. Voya Inv Mgmt Ltd Llc invested 0.07% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Nordea Ab has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Century Cos Inc accumulated 24,580 shares. Invesco Ltd holds 295,387 shares or 0.02% of its portfolio. 92,215 are held by Castleark Mngmt Limited Liability Co.

Since May 10, 2018, it had 0 buys, and 15 insider sales for $48.89 million activity. Patel Sunil also sold $10.15 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Thursday, August 16. LAMATTINA JOHN L sold 3,335 shares worth $850,292. Berkman Charles S had sold 2,813 shares worth $705,181. Another trade for 8,881 shares valued at $1.49M was made by FOEHR MATTHEW W on Thursday, May 10. HIGGINS JOHN L also sold $903,875 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares. 9,000 shares were sold by Davis Todd C, worth $2.16M.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Ligand Pharmaceuticals had 5 analyst reports since June 21, 2018 according to SRatingsIntel. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given on Wednesday, September 19 by H.C. Wainwright. Craig Hallum maintained the stock with “Buy” rating in Wednesday, June 27 report. The firm has “Neutral” rating by Roth Capital given on Wednesday, August 8. Below is a list of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) latest ratings and price target changes.

19/09/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $257 New Target: $270 Maintain
17/08/2018 Broker: Goldman Sachs Rating: Neutral New Target: $256 Initiates Coverage On
08/08/2018 Broker: Roth Capital Old Rating: Buy New Rating: Neutral Downgrade
27/06/2018 Broker: Craig Hallum Rating: Buy New Target: $230.0000 Maintain
21/06/2018 Broker: Argus Research Rating: Buy New Target: $260 Initiates Coverage On

The stock decreased 1.50% or $3.08 during the last trading session, reaching $202.59. About 1.27M shares traded or 207.85% up from the average. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 86.03% since October 13, 2017 and is uptrending. It has outperformed by 70.41% the S&P500.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company has market cap of $4.28 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. It has a 40.99 P/E ratio. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

More notable recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Investorplace.com which released: “10 Triple-A Stocks to Buy for the Rest of 2018” on September 28, 2018, also Nasdaq.com with their article: “Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for …” published on October 09, 2018, Fool.com published: “3 Top Mid-Cap Stocks to Buy Right Now” on October 06, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were released by: Streetinsider.com and their article: “Ligand Pharma (LGND) PT Raised to $280 at HC Wainwright” published on October 02, 2018 as well as Investorplace.com‘s news article titled: “The 10 Best Stocks to Buy Right Now” with publication date: September 24, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>